Mehandru, Saurabh
Colombel, Jean-Frederic
Article History
First Online: 14 December 2020
Competing interests
: J.-F.C. has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire and Takeda; consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix and Viela bio; and holds stock options in Intestinal Biotech Development. S.M. has received consulting fees from Genentech, GlaxoSmithKline and Takeda. S.M. and J.-F.C. have an unrestricted, investigator-initiated grant from Takeda to examine novel homing mechanisms to the gastrointestinal tract.